Ginkgo Bioworks Holdings Free Cash Flow Per Share Growth & History (DNA)
Ginkgo Bioworks Holdings's free cash flow per share was -$3.22 for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$3.22 | $4.14 | — |
| 2024 | 2024-12-31 | -$7.36 | -$0.45 | — |
| 2023 | 2023-12-31 | -$6.92 | $0.34 | — |
| 2022 | 2022-12-31 | -$7.25 | $14,598.56 | — |
| 2021 | 2021-12-31 | -$14,605.81 | -$4,883.51 | — |
| 2020 | 2020-12-31 | -$9,722.30 | -$5,996.93 | — |
| 2019 | 2019-12-31 | -$3,725.37 | — | — |
Ginkgo Bioworks Holdings quarterly free cash flow per share
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.76 | -$0.02 | — |
| Q1 2026 | 2026-03-31 | -$0.82 | $0.27 | — |
| Q3 2025 | 2025-09-30 | -$0.57 | $1.70 | — |
| Q2 2025 | 2025-06-30 | -$0.73 | $1.43 | — |
| Q1 2025 | 2025-03-31 | -$1.09 | $0.82 | — |
| Q3 2024 | 2024-09-30 | -$2.27 | -$0.67 | — |
| Q2 2024 | 2024-06-30 | -$2.17 | $2,879.86 | — |
| Q1 2024 | 2024-03-31 | -$1.92 | $3,675.27 | — |
| Q3 2023 | 2023-09-30 | -$1.60 | $1,640.05 | — |
| Q2 2023 | 2023-06-30 | -$2,882.03 | $1,421.52 | — |
| Q1 2023 | 2023-03-31 | -$3,677.18 | -$2,742.44 | — |
| Q3 2022 | 2022-09-30 | -$1,641.64 | -$1,125.56 | — |
| Q2 2022 | 2022-06-30 | -$4,303.55 | -$1,384.89 | — |
| Q1 2022 | 2022-03-31 | -$934.74 | $2,540.64 | — |
| Q3 2021 | 2021-09-30 | -$516.08 | — | — |
| Q2 2021 | 2021-06-30 | -$2,918.66 | — | — |
| Q1 2021 | 2021-03-31 | -$3,475.38 | — | — |
Ginkgo Bioworks Holdings free cash flow per share trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's free cash flow per share increased from -$9,722.30 to -$3.22, a change of $9,719.08. The latest reported quarter, Q2 2026, shows -$0.76.
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...